Recent updates

  • 23 Oct 2020Update on COVID-19 pandemicTopic:Coronavirus disease 2019 (COVID-19)
  • 21 Oct 2020Guidelines recommend measures to manage acute and chronic conditions during the COVID-19 pandemic: updatedTopic:Management of coexisting conditions in the context of COVID-19
  • 25 Aug 2020US FDA strengthens warning of risk of serious neuropsychiatric events associated with montelukast, and advises restricting use for allergic rhinitisTopic:Allergic rhinitis
  • 04 Aug 2020FDA strengthens warning of risk of serious neuropsychiatric events associated with montelukast, and advises restricting use for allergic rhinitisTopic:Chronic sinusitis
  • 30 Jun 2020FDA approves tenapanor for the treatment of constipation-predominant IBSTopic:Irritable bowel syndrome
  • 13 May 2020Simplified HCV treatment regimens now recommended in suitable patientsTopic:Hepatitis C
  • 06 May 2020FDA warns of the potential risk of pathogenic bacteria transmission associated with fecal microbiota transplantationTopic:Clostridium difficile-associated disease
  • 22 Apr 2020FDA requests withdrawal of ranitidine from the marketTopic:Gastroesophageal reflux disease
  • 07 Apr 2020EMA’s safety committee recommends suspension of ulipristal for uterine fibroids during ongoing review of liver injury riskTopic:Uterine fibroids
  • 19 Nov 2019US guidelines on community-acquired pneumonia updatedTopic:Community-acquired pneumonia
  • 09 Apr 2019Intravenous artesunate now first-line treatment for severe malaria in the USTopic:Malaria infection
  • 14 Nov 2018First-in-class treatment approved in the US for relapsed or refractory hairy cell leukemiaTopic:Hairy cell leukemia
  • 20 Sep 2018CDC alerts clinicians to a 'dramatic rise' in overdose deaths from fentanyl and its analogsTopic:Opioid overdose
  • 13 Jul 2018European Medicines Agency (EMA) strengthens measures to avoid use of valproate medicines in pregnancyTopic:Bipolar disorder in children